

## Kidney Suite Guideline Update - Committee Meeting

**Date:** 09/03/20

**Location:** NICE offices - Manchester

**Minutes:** Final

<b>Committee members present:</b>	
Anthony Wierzbicki (AW)	Present for notes 1 – 8
Clare Allinson (CA)	Present for notes 1 – 8
Virginia Aylett (VA)	Present for notes 1 – 8
Roy Connell (RC)	Present for notes 1 – 8
Deepa Kariyawasam (DK)	Present for notes 1 – 8
Arif Khwaja (AK)	Present for notes 2 - 8
Andrew Lewington (AL)	Present for notes 1 – 8
Fiona Loud (FL)	Present for notes 4 - 8
Catherine Pogson (CP)	Present for notes 1 – 8

<b>In attendance:</b>		
Chris Carmona (CC)	Senior Technical Analyst	Present for notes 1 – 8
Justine Karpusheff (JK)	Commissioning Manager	Present for notes 1 – 8
Yolanda Martinez (YM)	Technical Analyst	Present for notes 1 – 8
Rui Martins (RM)	Technical Analyst - Health Economics	Present for notes 1 – 8
Vonda Murray (VM)	Project Manager	Present for notes 1 – 8
Joshua Pink (JP)	Technical Adviser –	Present for notes 1 – 8

## Kidney Suite GComm 8 minutes

	Health Economics	
--	------------------	--

### Apologies:

Tara Bashford	Committee member
Ivan Benett	Committee member
Grainne Connolly	Committee member
Jan Dudley	Committee member
Nicola Thomas	Committee member
Rajib Pal	Committee member

### Observer:

Rachel Arche	Technical Analyst
--------------	-------------------

### 1. Welcome and objectives for the meeting

The Chair welcomed the committee members and attendees to the 8th committee meeting on Kidney Injury & Disease. The Chair welcomed to the meeting; committee members, NICE attendees, and observer.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included:

- Resolving some outstanding queries from the technical team
- Review and discussion of the evidence for children and young people with CKD, what is the accuracy of reagent strips for detecting protein and blood in urine.
- Review and discussion of the evidence for the best combination of measures of kidney function and markers of kidney damage to identify increased risk of progression for those with CKD?
- Discussion on economic modelling.

The Chair asked all committee members to verbally declare any interests that have arisen since the last meeting. The Chair and senior members of the Developer team noted that the interests previously declared, and any new interests did not prevent the attendees from fully participating in the meeting. New interests are noted below;

Name	Job title, organisation	Declarations of Interest, date	Type of interest	Decision taken
------	-------------------------	--------------------------------	------------------	----------------

## Kidney Suite GComm 8 minutes

		<b>declared</b>		
Arif Khwaja	Consultant Nephrologist, Sheffield Kidney Institute, Northern General Hospital	Lecture given to GPs and practice nurses on management of diabetic nephropathy-sponsored by NAPP pharmaceuticals. Honorarium received	Direct financial	Declare and Participate
<p>The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.</p>				
<p><b>2. Technical queries arising from the last meeting</b></p>				
<p>The Chair introduced YM, Technical Analyst, who presented the committee with a number of technical queries on the effects of interventions to lower proteinuria, and for those with stage 5 CKD, on dialysis, what amount of IV iron is most clinically and cost effective in managing anaemia.</p>				
<p><b>3. &amp; 4. RQ1.3 In children and young people with CKD, what is the accuracy of reagent strips for detecting protein and blood in urine?</b></p> <ul style="list-style-type: none"> <li>• <b>Clinical evidence</b></li> </ul>				
<p>The Chair introduced YM, Technical Analyst, who gave a presentation on the clinical evidence on the accuracy of reagent strips for detecting protein and blood in urine in children and young people with CKD. The committee discussed the evidence presented. The Chair thanked YM for her presentation.</p>				
<p><b>5.&amp; 6. RQ2.1 What is the best combination of measures of kidney function and markers of kidney damage to identify increased risk of progression in adults, children and young people with CKD?</b></p> <ul style="list-style-type: none"> <li>• <b>Clinical evidence</b></li> <li>• <b>Recommendations</b></li> </ul>				
<p>The Chair introduced OA, Technical Analyst, who gave a presentation on the clinical evidence for the best combination of measures of kidney function and markers of kidney damage to identify increased risk of progression in adults, children and young people with CKD. The committee discussed the evidence presented. The Chair thanked OA for her presentation.</p>				
<p><b>7. AOB</b></p>				
<p>The Chair introduced CC, Senior Technical Analyst who had some technical queries for the question on the biological and analytical variability of eGFR measurements in</p>				

## Kidney Suite GComm 8 minutes

people from BAME groups. The Chair thanked CC for facilitating the discussion.

### **8. Summary and next steps**

The Chair thanked the committee for their time and contribution to the meeting and reminded the committee of the start time of day 2 of the meeting.

**Date of next meeting:** 22/04/20 & 23/04/20

**Location of next meeting:** Day 1 – External venue (Coin Street Neighbourhood Centre, 108 Stamford Street, London SE1 9NH)

Day 2 – NICE offices – London